Samyang Pharmaceuticals

Samyang Biopharm is the healthcare and biopharmaceutical arm of South Korea's Samyang Group, focused on pharmaceuticals, gene therapeutics, and medical devices. The company markets commercial oncology products, transdermal patches, APIs, bioabsorbable surgical materials, hemostatic and anti-adhesion products, and aesthetic lifting threads. Its R&D effort spans difficult-to-make generics, drug delivery system-enabled formulations, long-acting injectables, and nucleic-acid delivery technologies. A central growth platform is SENS, a lipid-polymer nanoshell delivery technology being developed for mRNA vaccines and RNA therapeutics, including lung-, liver-, and CNS-targeted delivery. The company also operates an open-innovation outpost in Cambridge, Massachusetts through Samyang Biopharm USA.